US5858980A
(en)
*
|
1990-03-30 |
1999-01-12 |
Autoimmune, Inc. |
Peptide fragments of myelin basic protein
|
US7090982B2
(en)
|
1991-10-22 |
2006-08-15 |
The Governors Of The University Of Alberta |
Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
|
US6252040B1
(en)
|
1991-10-22 |
2001-06-26 |
The Governors Of The University Of Alberta |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
|
US5800808A
(en)
|
1994-05-24 |
1998-09-01 |
Veda Research And Development Co., Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
IL119989A0
(en)
*
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
EP1054880A1
(en)
*
|
1998-02-13 |
2000-11-29 |
Autoimmune, Inc. |
TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
|
WO2000005249A2
(en)
|
1998-07-23 |
2000-02-03 |
The President And Fellows Of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
EP1098902A4
(en)
|
1998-07-23 |
2002-07-24 |
Yeda Res & Dev |
TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
|
ES2527760T3
(es)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
ZA200102269B
(en)
|
1998-09-25 |
2002-03-19 |
Yeda Res & Dev |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use.
|
US6800287B2
(en)
*
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
WO2000020010A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
US7083777B1
(en)
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
ES2243450T3
(es)
*
|
2000-01-20 |
2005-12-01 |
Yeda Research And Development Co. Ltd. |
El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora.
|
CA2400374A1
(en)
*
|
2000-02-18 |
2001-08-23 |
Adrian Gilbert |
Oral, nasal and pulmonary dosage formualtions of copolymer 1
|
US7022663B2
(en)
*
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
AU7528001A
(en)
*
|
2000-06-05 |
2001-12-17 |
Teva Pharma |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
US20020037848A1
(en)
*
|
2000-06-07 |
2002-03-28 |
Michal Eisenbach-Schwartz |
Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
|
WO2002076503A1
(en)
*
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
WO2001097785A2
(en)
*
|
2000-06-20 |
2001-12-27 |
Caprion Pharmaceuticals Inc. |
Basic copolymers for the treatment of prion-related-disease
|
IL137460A0
(en)
*
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
SV2003000753A
(es)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
|
GB2369896A
(en)
|
2000-12-06 |
2002-06-12 |
Marconi Comm Ltd |
Tunable optical filter actuator
|
KR100442122B1
(ko)
*
|
2001-07-31 |
2004-07-30 |
한국전기연구원 |
영구 자석을 이용한 브러시리스 발전기
|
US7429374B2
(en)
*
|
2001-12-04 |
2008-09-30 |
Teva Pharmaceutical Industries, Ltd. |
Process for the measurement of the potency of glatiramer acetate
|
EP1429800B1
(en)
*
|
2001-12-06 |
2009-02-11 |
Yeda Research And Development Co., Ltd. |
Vaccine and use thereof for treatment of amyotrophic lateral sclerosis
|
US20060057107A1
(en)
*
|
2001-12-21 |
2006-03-16 |
Shaked Ze Ev |
Combination treatment for multiple sclerosis
|
ATE548045T1
(de)
|
2003-01-07 |
2012-03-15 |
Yeda Res & Dev |
Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung
|
MXPA05007711A
(es)
*
|
2003-01-21 |
2005-09-30 |
Yeda Res & Dev |
Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino.
|
EP1603530A1
(en)
*
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
US20040219160A1
(en)
|
2003-03-31 |
2004-11-04 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic immunomodulators for the treatment of asthma and allergy
|
NZ546379A
(en)
*
|
2003-10-31 |
2010-04-30 |
Teva Pharma |
Nanoparticles for drug delivery
|
EP1684797A1
(en)
|
2003-11-12 |
2006-08-02 |
Yeda Research and Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
JP4808631B2
(ja)
|
2003-12-09 |
2011-11-02 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
精神医学的障害の治療用のコポリマー1を含む方法及びワクチン
|
CA2556152A1
(en)
*
|
2004-02-02 |
2005-08-18 |
Mixture Sciences, Inc. |
Peptide mixtures with immunomodulatory activity
|
CA2558655A1
(en)
*
|
2004-03-01 |
2005-09-15 |
Kai W. Wucherpfennig |
Methods and compositions for treatment of autoimmune diseases
|
CA2558380A1
(en)
*
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
WO2005120542A2
(en)
|
2004-05-07 |
2005-12-22 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
SG186686A1
(en)
|
2004-06-25 |
2013-01-30 |
Id Biomedical Corp Quebec |
Compositions and methods for treating neurological disorders
|
NZ554018A
(en)
|
2004-09-09 |
2009-06-26 |
Teva Pharma |
Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
|
WO2006029411A2
(en)
*
|
2004-09-09 |
2006-03-16 |
Yeda Research And Development Co. Ltd. |
Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
|
AR052321A1
(es)
*
|
2004-10-29 |
2007-03-14 |
Sandoz Ag |
Procesos para la preparacion de un polipeptido
|
US8324641B2
(en)
*
|
2007-06-29 |
2012-12-04 |
Ledengin, Inc. |
Matrix material including an embedded dispersion of beads for a light-emitting device
|
US20090191173A1
(en)
*
|
2004-11-29 |
2009-07-30 |
Michal Eisenbach-Schwartz |
Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
|
US20060172942A1
(en)
*
|
2005-02-02 |
2006-08-03 |
Teva Pharmaceutical Industries, Ltd. |
Process for producing polypeptide mixtures using hydrogenolysis
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
SI1848415T1
(sl)
*
|
2005-02-17 |
2013-08-30 |
Teva Pharmaceutical Industries Ltd. |
Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze
|
EP1891233A4
(en)
*
|
2005-04-25 |
2010-03-24 |
Yeda Res & Dev |
MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
|
WO2007081975A2
(en)
*
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
US8206726B2
(en)
|
2006-02-06 |
2012-06-26 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic polysaccharides for promotion of immune system maturation and health
|
WO2007120834A2
(en)
|
2006-04-13 |
2007-10-25 |
Peptimmune, Inc. |
Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
|
EP2013628B1
(en)
|
2006-04-28 |
2016-01-06 |
Momenta Pharmaceuticals, Inc. |
Methods of evaluating peptide mixtures
|
KR100831796B1
(ko)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
|
US9089509B2
(en)
|
2006-06-28 |
2015-07-28 |
Yeda Research And Development Co., Ltd. |
Method of treatment of age-related macular degeneration
|
AU2007269140A1
(en)
*
|
2006-07-05 |
2008-01-10 |
Momenta Pharmaceuticals, Inc. |
Improved process for the preparation of copolymer-1
|
EP2381254B2
(en)
|
2007-06-21 |
2017-07-19 |
Momenta Pharmaceuticals, Inc. |
Copolymer assay
|
US20090029766A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Lutnick Howard W |
Amusement gaming access and authorization point
|
WO2009016643A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
EP2586460A1
(en)
|
2007-10-16 |
2013-05-01 |
Peptimmune, Inc. |
Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes
|
JP2011503104A
(ja)
|
2007-11-09 |
2011-01-27 |
カリフォルニア インスティテュート オブ テクノロジー |
免疫調節化合物ならびに関連組成物および方法
|
EA201070656A1
(ru)
*
|
2007-11-28 |
2010-12-30 |
Тева Фармасьютикал Индастриз, Лтд. |
Способ задержки начала проявления клинически определенного рассеянного склероза
|
WO2009129018A1
(en)
|
2008-04-16 |
2009-10-22 |
Momenta Pharmaceuticals, Inc. |
Analysis of amino acid copolymer compositions
|
WO2010017292A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Scinopharm Taiwan, Ltd. |
Synthesis of glatiramer acetate
|
PL2307448T3
(pl)
*
|
2008-08-07 |
2015-10-30 |
Sigma Aldrich Co Llc |
Wytwarzanie polilizyny i poliornityny o małym ciężarze cząsteczkowym z wysoką wydajnością
|
US9617313B2
(en)
|
2008-12-24 |
2017-04-11 |
Synthon Bv |
Process for purifying a polymer mixture
|
WO2010115175A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Momenta Pharmaceticals, Inc. |
Control of copolymer compositions
|
AU2009347384B2
(en)
*
|
2009-06-04 |
2014-10-23 |
Council Of Scientific & Industrial Research |
A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
|
DK2275086T3
(da)
*
|
2009-07-15 |
2012-07-09 |
Teva Pharma |
Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
RS52885B
(en)
|
2009-08-20 |
2014-02-28 |
Yeda Research And Development Co. Ltd. |
LOW-FREQUENCY GLATIRAMER ACETATOM THERAPY
|
JP5916622B2
(ja)
|
2010-01-04 |
2016-05-11 |
マピ ファーマ リミテッド |
グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
EP2523668A1
(en)
|
2010-01-13 |
2012-11-21 |
Ramot at Tel-Aviv University Ltd |
Treatment of multiple sclerosis
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
EP2555753B1
(en)
|
2010-04-07 |
2018-08-01 |
California Institute of Technology |
Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
|
AU2011248663A1
(en)
*
|
2010-04-27 |
2012-11-08 |
Dr. Reddy's Laboratories Ltd. |
Preparation of polypeptides and salts thereof
|
JP2013530949A
(ja)
|
2010-05-20 |
2013-08-01 |
エル ラウンド ジューン |
抗原特異的Treg並びに関連する組成物、方法及びシステム
|
RU2013108828A
(ru)
*
|
2010-07-29 |
2014-09-10 |
Др. Редди'С Лабораторис Лтд. |
Маркеры молекулярной массы глатирамера ацетата
|
MX347871B
(es)
|
2010-10-11 |
2017-05-16 |
Teva Pharmaceutical Ind Ltd * |
Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
|
EP2675824B1
(en)
|
2011-02-14 |
2017-09-27 |
USV Private Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
ES2601892T3
(es)
|
2011-04-21 |
2017-02-16 |
Mapi Pharma Limited |
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
|
US20140348861A1
(en)
|
2011-05-05 |
2014-11-27 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
WO2013009885A2
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation of copolymer diethylamide
|
WO2013009864A1
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Structure assessment of heterogeneous polypeptide mixtures
|
JP6273200B2
(ja)
|
2011-07-12 |
2018-01-31 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
脂質含有psa組成物、その単離の方法および使用の方法
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
EA201490749A1
(ru)
|
2011-10-10 |
2014-09-30 |
Тева Фармасьютикал Индастриз Лтд. |
Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
|
WO2013139728A1
(en)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Glatiramer acetate human monocyte cell-based potency assay
|
EP2642290A1
(en)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Glatiramer acetate human monocytic cell line-based potency assay
|
US20140045740A1
(en)
*
|
2012-08-13 |
2014-02-13 |
Momenta Pharmaceuticals, Inc. |
Analysis of glatiramer acetate
|
WO2014058976A2
(en)
|
2012-10-10 |
2014-04-17 |
Teva Pharmaceutical Industries Ltd. |
Biomarkers predictive for clinical response for glatiramer acetate
|
WO2014060942A2
(en)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
DK2774639T3
(en)
|
2013-03-08 |
2015-01-12 |
Teva Pharma |
Reusable injection device for a syringe
|
PT2774640E
(pt)
|
2013-03-08 |
2015-02-09 |
Teva Pharma |
Dispositivo injector reutilizável para seringa
|
WO2014159685A2
(en)
|
2013-03-14 |
2014-10-02 |
Mylan Inc. |
Glatiramer acetate response biomarker mrna potency assay
|
WO2014173463A1
(en)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Glatiramer acetate human monocytic cell line-based potency assay
|
JP2016521284A
(ja)
|
2013-05-10 |
2016-07-21 |
カリフォルニア インスティチュート オブ テクノロジー |
大腸ガンのプロバイオティクスによる防止および処置
|
CN103265624B
(zh)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
格拉替雷的制备方法
|
CN104371012A
(zh)
*
|
2013-08-12 |
2015-02-25 |
深圳翰宇药业股份有限公司 |
一种合成醋酸格拉替雷的方法
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
CA2928084A1
(en)
|
2013-10-24 |
2015-04-30 |
Mylan Inc. |
Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
|
JP2017503169A
(ja)
|
2013-12-31 |
2017-01-26 |
イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド |
オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断
|
US10144778B2
(en)
|
2014-03-12 |
2018-12-04 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
CN104844697B
(zh)
|
2014-09-26 |
2018-10-23 |
深圳翰宇药业股份有限公司 |
醋酸格拉替雷的制备方法
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
US11047855B2
(en)
|
2015-03-01 |
2021-06-29 |
Immunarray Ltd. |
Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
|
WO2016201342A1
(en)
|
2015-06-10 |
2016-12-15 |
California Institute Of Technology |
Sepsis treatment and related compositions methods and systems
|
JP6918365B2
(ja)
|
2015-08-19 |
2021-08-11 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
脂質化psa組成物および方法
|
EP3147667B1
(en)
|
2015-09-24 |
2019-06-12 |
CHEMI S.p.A. |
Analysis of the molecular weight distribution of complex polypeptide mixtures
|
ES2707500T3
(es)
|
2015-11-23 |
2019-04-03 |
Chemi Spa |
Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
|
CN107522774B
(zh)
*
|
2016-06-22 |
2021-07-02 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
|
US20210220428A1
(en)
|
2016-06-30 |
2021-07-22 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
US11491181B2
(en)
|
2016-07-15 |
2022-11-08 |
President And Fellows Of Harvard College |
Glycolipid compositions and methods of use
|
BR112019003131A2
(pt)
|
2016-08-28 |
2019-05-21 |
Mapi Pharma Ltd. |
processo para preparar micropartículas contendo acetato de glatirâmero
|
JP7193448B2
(ja)
|
2016-08-31 |
2022-12-20 |
マピ ファーマ リミテッド |
酢酸グラチラマーを含むデポシステム
|
MX2019010174A
(es)
|
2017-03-26 |
2019-10-15 |
Mapi Pharma Ltd |
Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
|
AU2017414803A1
(en)
|
2017-05-15 |
2019-12-05 |
Mapi Pharma Ltd. |
Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
|
WO2018211498A1
(en)
|
2017-05-15 |
2018-11-22 |
Stem Cell Medicine Ltd. |
Treatment of multiple sclerosis with adipose-derived stem cells
|
WO2019175869A1
(en)
|
2018-03-12 |
2019-09-19 |
Yeda Research And Development Co. Ltd |
Treatment of a heart disease
|